ERBB2 and neoplasm: As expected, radioactivity in the blood pool was comparable for each cohort regardless of the injected immuno-PET agent, and in vivo targeting of the HER2/neu tumor was efficient suggesting that the chelator did not alter trastuzumab specificity in vivo.